The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...

2025-03-06 08:01发布于江苏药明康德官方账号 罗氏（Roche）今天宣布，美国FDA已接受该公司为抗CD20抗体obinutuzumab递交的补充生物制品许可申请（sBLA ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

More patients in the obinutuzumab group than the placebo group had a complete renal response at week 76 with a prednisone ...

The head-to-head GALLIUM trial showed the newer drug Gazyva (obinutuzumab)produced a 34% reduction in the risk of disease progression or death in patients with previously untreated FL compared to ...

Among 28 previously untreated patients, the overall response rate reached 67.9% (95% CI 47.6-84.1) following six cycles of atezolizumab (Tecentriq) plus venetoclax (Venclexta) and obinutuzumab ...